Zealand Pharma A/S (OTCMKTS:ZLDPF) Sets New 12-Month Low - Here's What Happened

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report)'s share price reached a new 52-week low during trading on Tuesday . The stock traded as low as $57.23 and last traded at $57.23, with a volume of 859 shares changing hands. The stock had previously closed at $63.79.

Wall Street Analyst Weigh In

Separately, William Blair upgraded Zealand Pharma A/S from a "hold" rating to a "strong-buy" rating in a research note on Friday, March 7th.

Zealand Pharma A/S Trading Down 4.6%

The company has a debt-to-equity ratio of 0.03, a current ratio of 25.10 and a quick ratio of 25.07. The business's fifty day simple moving average is $66.40 and its 200 day simple moving average is $84.34. The stock has a market cap of $4.06 billion, a price-to-earnings ratio of -22.98 and a beta of 0.74.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.67) earnings per share for the quarter, beating analysts' consensus estimates of ($0.77) by $0.10. The business had revenue of $1.14 million during the quarter, compared to the consensus estimate of $248.61 million. Zealand Pharma A/S had a negative net margin of 2,127.09% and a negative return on equity of 13.40%. On average, research analysts predict that Zealand Pharma A/S will post -2.19 EPS for the current year.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.